Versor Investments LP Buys New Holdings in Phreesia, Inc. (NYSE:PHR)

Versor Investments LP purchased a new position in shares of Phreesia, Inc. (NYSE:PHR) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 30,441 shares of the company’s stock, valued at approximately $694,000. Versor Investments LP owned about 0.05% of Phreesia at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. International Assets Investment Management LLC boosted its position in shares of Phreesia by 2,179.7% in the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after buying an additional 1,395 shares during the period. nVerses Capital LLC raised its stake in shares of Phreesia by 76.5% during the second quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after purchasing an additional 1,300 shares during the period. EntryPoint Capital LLC acquired a new position in shares of Phreesia during the first quarter worth $169,000. Quadrature Capital Ltd purchased a new position in shares of Phreesia in the first quarter valued at $202,000. Finally, Lombard Odier Asset Management USA Corp acquired a new stake in Phreesia during the 2nd quarter valued at $202,000. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Phreesia

In related news, CEO Chaim Indig sold 5,295 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total transaction of $123,108.75. Following the transaction, the chief executive officer now owns 1,223,736 shares in the company, valued at $28,451,862. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Chaim Indig sold 5,295 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total value of $123,108.75. Following the completion of the sale, the chief executive officer now owns 1,223,736 shares in the company, valued at $28,451,862. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel Allison C. Hoffman sold 1,212 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $21.03, for a total transaction of $25,488.36. Following the completion of the transaction, the general counsel now owns 119,791 shares in the company, valued at approximately $2,519,204.73. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 44,107 shares of company stock valued at $1,035,226 over the last three months. 5.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Royal Bank of Canada reissued a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a research report on Friday, September 27th. Needham & Company LLC reiterated a “buy” rating and set a $29.00 price target on shares of Phreesia in a research report on Thursday, September 5th. JPMorgan Chase & Co. raised their price target on shares of Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Monday, September 9th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $34.00 price target on shares of Phreesia in a research note on Thursday, September 5th. Finally, DA Davidson reiterated a “buy” rating and issued a $32.00 target price on shares of Phreesia in a report on Thursday, September 5th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, Phreesia presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.42.

Phreesia Stock Up 4.6 %

NYSE PHR opened at $22.36 on Thursday. Phreesia, Inc. has a 12-month low of $14.55 and a 12-month high of $29.16. The firm’s 50 day moving average is $21.52 and its 200-day moving average is $22.03. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.03.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Wednesday, September 4th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.06. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. The company had revenue of $102.12 million for the quarter, compared to analyst estimates of $101.76 million. Equities research analysts predict that Phreesia, Inc. will post -1.23 EPS for the current fiscal year.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.